Noticias y Actividades de HiberCell

HiberCell tiene presencia directa en 2 países.

HiberCell posee 7 subsidiarias incluyendo Genuity Science, STA Pharmaceutical y WuXi AppTec.

Ellos se encuentran en:

• Biotecnología88%
• Farmacia13%

Ver el organigrama con sus 101 ejecutivos principales

Biografías más buscadas en HiberCell

• Steven Gillis, Chairman and Acting Chief Executive Officer
• Cindy Jacobs, Director
• Jim Sullivan, Director

Crear su alerta
para seguir los movimientos de los ejecutivos en HiberCell.

HiberCell tiene 2.405 competidores entre los que se incluyen Eurofins (Luxemburgo), Lonza (Suiza) y BioNTech (Alemania).

Popular M&A news in Biotecnología

• IMU Biosciences acaba de anunciar una recaudación de fondos de 53 millones de dólares. (publicado el 3 de junio de 2026).
• NewLimit acaba de anunciar una recaudación de fondos de 435 millones de dólares. (publicado el 3 de junio de 2026).
• Rallybio and Avenzo Therapeutics have announced they will merge  (publicado el 1 de junio de 2026)..

Otros contactos sugeridos en el sector Biotecnología

• Jakob Uszkoreit - Co-Founder and Chief Executive Officer en Inceptive
• Jan Van de Winkel - President and Chief Executive Officer en Genmab
• Valerie Hanote - Non-Executive Director en Eurofins

Saber más sobre el sector Biotecnología

Últimos comunicados de prensa de HiberCell

• HiberCell to Present Preliminary Results from the Phase 1b Trial of GCN2 Activator HC-7366 When Combined with WELIREG® (belzutifan) for the Treatment of Late-Line Clear Cell Renal Cell Carcinoma (ccRCC) at the Upcoming 2026 ASCO Annual Meeting - HiberCell
• HiberCell to Present Preclinical Data Demonstrating the Enhanced Antitumor Activity of HC-7366 in Combination with VEGFR-TKIs in Clear Cell Renal Cell Carcinoma (ccRCC) - HiberCell
• AVEO Oncology, an LG Chem company, and HiberCell Enter Into an Exclusive Development and Option Agreement for First-in-Human Compound - HiberCell
• HiberCell Announces Successful Completion of Dose Escalation and Enrollment Update for Ph1b Study Evaluating HC-7366 in Combination with WELIREG® (belzutifan) in Advanced ccRCC - HiberCell
• HiberCell Announces First Patient Dosed in Phase 1b Clinical Trial, Evaluating HC-7366 in Combination with Venetoclax and Azacitidine for the Treatment of Acute Myeloid Leukemia (AML) - HiberCell
• HiberCell's Board of Directors Appoints Steven Gillis, Ph.D., the Company's Current Chairman of the Board, as Chairman and Acting CEO - HiberCell
• Jonathan Lanfear Steps Down from Role as President and CEO. HiberCell's Board of Directors Appoints Steven Gillis, Ph.D., the Company's Current Chairman of the Board, as Chairman and Acting CEO. - HiberCell
• HiberCell Announces First Patient Dosed in Clinical Collaboration with Merck, Evaluating HC-7366 in Combination with WELIREG® (belzutifan) in patients with advanced ccRCC - HiberCell
• HiberCell, Inc. Announces Clinical Collaboration with Merck to Evaluate HC-7366, an Activator of ISR Kinase GCN2, in Combination with WELIREG® (belzutifan) in a Phase 1b Study of Patients with Clear Cell Renal Cell Carcinoma (ccRCC) - HiberCell
• HiberCell Announces Successful Completion and Interim Results of Phase 1 Study of Novel PERK Inhibitor, HC-5404, in Solid Tumors and Maps Forward Path as Monotherapy and in Combinations - HiberCell
• View more press releases Close

Redes sociales sobre HiberCell

• HiberCell en Wikipedia, Google News y Yahoo Finance
• HiberCell en LinkedIn, Twitter y YouTube